The European Facility Survey Questionnaire (EFSQ) is a data collection instrument applicable in any European country or in any country worldwide interested in surveying facilities that provide interventions to drug users. The aim of the EFSQ is to collect information from the facilities across drug treatment systems on their administrative characteristics, client utilisation, staffing and quality management, and core interventions, while accounting for their diversity.
At a time of increased debate on the laws controlling the use of cannabis in the European Union, this report answers some of the questions most often asked about cannabis legislation. Using a question and answer format, basic definitions and the obligations of countries under international law are set out in a section on ‘What is cannabis and what are countries’ obligations to control it?‘ Two following sections examine the links and disparities between the content of the laws and their guidelines on the one hand and the actual implementation of the laws on the other.
This publication presents the data and findings of the risk assessment on methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), carried out by the extended Scientific Committee of the EMCDDA on 22 July 2016. MDMB-CHMICA is the first synthetic cannabinoid receptor agonist to be risk-assessed by the EMCDDA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 February 2017, the Council decided that MDMB-CHMICA should be subject to control measures across the Member States.
The central UN policy-making body in drug-related matters, opens its 60th session in Vienna.
The network will be collecting data from new hospital ‘sentinel’ centres in eight European cities
Community coalitions are a strategy to coordinate activities and resources to prevent adolescent substance use and delinquent behaviour. They can help mobilise communities in prevention and health promotion initiatives.
The Communities That Care (CTC) approach sets out to reduce adolescent health and behaviour problems. It does so by identifying strong risk factors and weak protective factors experienced by this group and then selecting tested and effective prevention and early intervention programmes to address them.
The documents published cover the period 2017-19.
The Justice and Home Affairs (JHA) agencies’ network was established in 2006 to boost cooperation in the migration and security fields and to develop synergies in areas of common interest, such as operational work, training and external relations. Since the EMCDDA and EIGE joined in 2011, the network has been composed of nine agencies (CEPOL, EASO, EIGE, EMCDDA, eu-LISA, Eurojust, Europol, FRA and Frontex).
The EMCDDA Single Programming Document (SPD) for the period 2017–19, which includes the 2017 work programme, is the first work programme to be implemented under the new EMCDDA Strategy 2025. Priority in 2017 will be given to improving core monitoring tasks and to operating the EU Early Warning System under a new regulation on new psychoactive substances, which is expected to enter into force in the course of the year.
MDMB-CHMICA is a synthetic cannabinoid and will be subject to ‘control measures’ throughout the EU.
In September 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly known as acryloylfentanyl, through a joint assessment. The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on acryloylfentanyl as stipulated by Article 5.1 of the Council Decision.
In this issue: Lisbon Addictions 2017 | Revamped Healthy Nightlife Toolbox |
EMCDDA chairs JHA agencies’ network | Germany enacts new law to control
new psychoactive substances | European drugs summer school 2017 |
EMCDDA products and services | Scientific Committee begins new mandate
The Directors of FRA and the EMCDDA are at the European Parliament today, presenting highlights and priorities for the network.
HIV experts from across the EU will discuss how to reverse the HIV trend and to prepare Europe to achieve the set target of ending AIDS by 2030.
EMCDDA Director Alexis Goosdeel is in Malta today where he will speak at the opening session of a two-day conference on HIV, co-organised by the Maltese EU Presidency and the European Centre for Disease Prevention and Control (ECDC).
As of today, the EMCDDA will be hosting an online Healthy Nightlife Toolbox (HNT), which collects and provides information on good-practice interventions targeting drug and alcohol use and related problems among young people in nightlife settings.
Illicit drug markets have a global reach. This paper provides an overview of EU policies and responses to the production and trafficking of illicit drugs within the international context. It considers the different strategic areas involved, the EU structures concerned, along with some of the key measures currently being implemented by the EU and its international partners. Drug supply reduction actions cut across policy areas. These include illicit drug policy, security, organised crime, and maritime and regional cooperation policy.
The results of a study on national drug trafficking laws and their application in the Member States of the European Union are presented in this report. It is based on an analysis of the national laws and on the opinions of legal practitioners — judges, prosecutors and defence lawyers — from 26 countries. The penalties set out in national laws for trafficking cannabis, amphetamine, cocaine and heroin are compared with the sentencing outcomes expected by the legal practitioners, including penalties imposed and the estimated time likely to be spent in prison.
The EU Drug Markets Report 2016 is the second comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. Taking an evidence-based approach, the report considers the impacts of the drug market on wider society and reviews the markets for cannabis, heroin, cocaine, amphetamine, methamphetamine, MDMA and new psychoactive substances. It also provides concrete action points to inform policy development at EU and national level.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) would like to clarify that, while its activities include reporting on online drug markets, it is not recruiting hackers or rehabilitated traffickers to tackle drug trafficking on the internet, as stated in the various media articles this week.
This week, the EMCDDA embarks on a year-long presidency of a network of nine EU Justice and Home Affairs agencies (‘JHA network’), which play key advisory, operational and coordination roles in implementing EU priorities in the areas of freedom, security and justice.
Under international laws, cultivation, supply and possession of cannabis should be allowed only for ‘medical and scientific purposes’. In general, possession of the drug for personal use should be a crime, to deter use, and most countries make this punishable by imprisonment. In recent years, however, several jurisdictions have reduced their penalties for cannabis users, and some have permitted supply of the drug, allowing us to observe different control models and their consequences.
The latest findings from the largest European project in the emerging science of wastewater analysis are presented today by the Europe-wide SCORE group, in association with the EMCDDA. The project analysed wastewater in over 50 European cities in 18 European countries in March 2016 to explore the drug-taking behaviours of their inhabitants.
Quality standards in drug demand reduction will be the focus of discussions today at an EMCDDA meeting gathering experts from seven countries. The purpose of the meeting is to present how the ‘Council conclusions on the implementation of minimum quality standards in drug demand reduction in the EU’.
On 8 December, the Council adopted its position on a package reforming the legislation on new psychoactive substances (NPS).
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report is based on the indicator’s annual expert meeting, held in Lisbon in June 2016, which brought together national experts from the 28 EU Member States, Norway and Turkey.
EMCDDA Director Alexis Goosdeel is at the Vatican City today where he will speak at a two-day workshop entitled ‘Narcotics: problems and solutions of this global issue’. The event is organised by the Pontifical Academies of Sciences (PAS).
Representatives of candidate, potential candidate and neighbouring countries of the EU are joining members of the EMCDDA’s Reitox network in Lisbon today for the kick-off of the agency’s fifth Reitox week.
The European new psychoactive substances (NPS) market has increased at a speed that established drug control laws struggle to match. Various countries have therefore introduced new legal responses to this phenomenon, based either on existing laws that focused on consumer or health protection or medicinal products, or by developing innovative new legislation. In 2014, the Court of Justice of the European Union ruled that substances are not medicinal products if they do not have beneficial effects on human health, thus restricting the use of such laws for NPS control.
Eurojust and the EMCDDA have released today their first joint publication entitled 'New psychoactive substances in Europe. Legislation and prosecution — current challenges and solutions'.